Please assess the completion status of the following clinical trial:

Trial Title: ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ASA PS 1-3~* Patients who are scheduled to undergo upper/lower limb surgery under the monitored anesthetic care with remimazolam~Exclusion Criteria:~* Patients who refuse to participate in this study~* Patients with hypersensitivity to benzodiazepine or flumazenil~* Patients with severe renal/hepatic disease~* Patients with drug/alcohol abuse~* Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically~* Patients with difficulty in communication~* Patients with severe obstructive sleep apnea or other airway problems~* Patients contraindicated to regional anesthesia~* Patients judged to be inappropriate for this study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remimazolam (Type: EXPERIMENTAL): A loading dose of remimazolam is administered for sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).